Table 3

The effects of medical therapies on the progression of diabetic retinopathy in the ACCORD and ACCORDION Studiesa

ACCORDbACCORD (photographic grading data only)cACCORDIONd
n/N (%)Adjusted OR (95% CI)P valuen/N (%)Adjusted OR (95% CI)P valuen/N (%)Adjusted OR (95% CI)P value
Glycemia therapy0.67 (0.51–0.87)0.0030.61 (0.46–0.82)0.0010.42 (0.28–0.63)<0.0001
 Intensive104/1,429 (7.3)81/1,418 (5.7)38/658 (5.8)
 Standard149/1,427 (10.4)126/1,418 (8.9)83/652 (12.7)
Dyslipidemia therapy0.60 (0.42–0.87)0.0060.54 (0.36–0.80)0.0021.13 (0.71–1.79)0.60
 Simvastatin/fenofibrate52/806 (6.5)41/802 (5.1)47/399 (11.8)
 Simvastatin/placebo80/787 (10.2)70/781 (9.0)37/363 (10.2)
Antihypertensive therapy1.23 (0.84–1.79)0.290.97 (0.64–1.47)0.881.21 (0.61–2.40)0.59
 Intensive67/647 (10.4)48/640 (7.5)21/280 (7.5)
 Standard54/616 (8.8)48/613 (7.8)16/268 (6.0)
  • aResults of likelihood-ratio tests from logistic regression models.

  • bPreviously reported composite outcome: progression of 3 or more steps on the ETDRS severity scale of diabetic retinopathy, vitrectomy, or photocoagulation for the treatment of proliferative diabetic retinopathy.

  • cOutcome consists only of the progression of 3 or more steps on the ETDRS scale for the classification of diabetic retinopathy.

  • dAt 8 years, photographic grading data only.